Bovine growth hormone: human food safety evaluation

Dairy products and breast cancer: the IGF-I, estrogen, and bGH hypothesis

Research on the role of dietary factors in breast cancer causation has focused predominantly on fat intake. While some studies have examined associations between breast cancer rates and consumption of whole milk, there has been less attention given to dairy products in general. Dairy products contain both hormones and growth factors, in addition to fat and various chemical contaminants, that have been implicated in the proliferation of human breast cancer cells. This literature review evaluates the epidemiological and mechanistic evidence linking dairy consumption with breast cancer risk.

Combined insulin-like growth factor-1 and growth hormone improves weight loss and wound healing in burned rats

The anabolic effects of growth hormone (GH) in burned patients appear to act both directly and through insulin-like growth factor-1 (IGF-1). We, therefore, hypothesize that exogenous GH plus IGF-1 will attenuate increases in metabolism and lean muscle wasting while promoting wound healing.

MATERIALS AND METHODS

Rats, each weighing 440-470 g, were given a 35% total body surface area, full-thickness scald burn and divided into four groups to receive placebo (burned controls), bovine GH (2.5 mg/kg/day), IGF-1 (2.0 mg/kg/day), or bovine GH plus rhIGF-1 (2.5 + 2.0 mg/kg/day), respectively, for 8 weeks.

RESULTS

Total body weight gain after 8 weeks averaged 110 g for GH plus IGF-1 compared with gains of 49 and 11 g for GH or IGF-1 alone, respectively. Burned controls lost 24 g. Metabolic rates were significantly reduced in all groups receiving growth hormones. Gastrocnemius muscle dry weight was significantly increased in those receiving GH plus IGF-1 compared with GH and IGF-1 alone or burned controls (p < .01).

CONCLUSIONS

Data show that GH plus IGF-1 synergistically increased lean muscle weight, total body weight, and was more effective in re-epithelialization of the burn wound than either GH or IGF-1 alone.

Disposition of ingested olestra in weanling mini-pigs

The disposition of ingested olestra in Hanford mini-pigs was examined by following a single oral gavage dose of radiolabelled (U-14C-sucrose) olestra Eight dosed animal (four/sex) and one undosed animal were killed 1, 3 and 7 days after dosing, and tissues were collected and counted. Urine and faeces were collected continuously and counted. Tissue lipids were extracted and analysed for intact radiolabelled olestra by size exclusion chromatography. Sucrose will be excreted in urine if olestra is absorbed and metabolized. Mean recovery of radiolabel was 96.6% of the administered dose. Of the recovered radiolabel, more than 99.4%, on average, was not absorbed and found in faeces, or cage and animal wash solutions. The absorbed radiolabel (0.6%), was distributed across the carcass, all tissues and blood, or excreted in urine. This radiolabel primarily came from the metabolism of glucose and fructose resulting from the hydrolysis of the trace levels of penta- and lower sucrose esters present in the test material. No radiolabel was found in the olestra-containing fraction of liver lipids, the primary measure of absorbed and non-metabolized olestra, at a detection limit of 0.0002% of dose. A conservative estimate of the amount of 14C-sucrose excreted in the urine was 0.0012%. The total absorption of intact olestra was thus less than 0.0014% of the dose, the sum of the two measures. These results indicate that intact olestra is essentially not absorbed by the weanling mini-pig, an animal with a young developing gastrointestinal tract similar to that of young children (2-5 yr).

Insulin-like growth factors in milk and mammary gland

Milk contains insulin-like growth factor I and II (IGF-I and IGF-II) and four IGF binding proteins (IGFBP). Their concentrations are highest prepartum and early postpartum, coinciding with maximal proliferation of mammary cells and the time when the infant gut is the least developed. This has lead to the suggestion that IGFs may be important for the growth and development of the mammary gland and that IGFs in milk play a role in promoting development of the gastrointestinal tract of the newborn. IGF-I and, to a lesser extent, IGF-II can stimulate milk yield and blood flow in goats when infused directly into the mammary gland, suggesting they may also be important in supporting established lactation. Thus IGFs may have a dual function in the mammary gland, establishing and maintaining the maternal mammary system and, once secreted into milk, supporting gastrointestinal development in the newborn.

The potential physiological significance of milk-borne hormonally active substances for the neonate

This article reviews the presence and potential physiological significance of hormones and hormonally active substances (including growth factors) in human milk. Human milk has been found to contain several nonpeptide hormones and many peptide hormones and growth factors. In contrast to human breast milk, infant formulae lack some hormonally active peptides. There is little data concerning the effects of these agents on human neonates. Studies in immature experimental animals showing effects of orogastically administered hormones are summarized. The problems of supplementation of infant formula are discussed. Since hormones are present in the milk as a "cocktail" of potentially agonistic and antagonistic substances, one question is whether supplementation with a single agent would disturb this balance.

Modulation of proliferation, second messenger levels, and morphotype expression of the rat intestinal epithelial cell line IEC-6 by fermented milk

Trophic effects of milk fermented with Lactobacillus helveticus, Lactobacillus paracasei ssp. paracasei, Bifidobacterium sp., or the combination of Lactobacillus bulgaricus and Streptococcus thermophilus (yogurt) were studied on the IEC-6 intestinal epithelial cell line. Incorporation of [methyl-3H]thymidine, mitochondrial dehydrogenase activities, cyclic AMP production, and differentiation of levels of the IEC-6 strain were evaluated between the 15th and 30th passage in culture. All fermented and unfermented milks enhanced trophic responses of IEC-6 cells in a dose-dependent manner. Compared with the corresponding milks, supernatant fractions were more effective in stimulating mitochondrial dehydrogenase response. Fermented milk supernatants were also more effective than the corresponding unfermented fractions. Increases in DNA synthesis and cyclic AMP confirmed the activation observed with mitochondrial dehydrogenase. Yogurt induced the more trophic response with an increased number of the more differentiated cell morphotype. Fermentation with L. casei also demonstrated an important trophic adaptation of IEC-6 cells. Milk processing by lactic acid bacteria enhanced trophic and proliferation responses of intestinal epithelial cell line IEC-6. These results suggested that IEC-6 cells could represent an accurate and easy in vitro model for testing the trophic quality of various nutrients and for an optimization of physiological digestive functions.

Unlabeled milk from cows treated with biosynthetic growth hormones: a case of regulatory abdication

Levels of insulin-like growth factor-1 (IGF-1) are substantially elevated and more bioactive in the milk of cows hyperstimulated with the biosynthetic bovine growth hormones rBGH, and are further increased by pasteurization. IGF-1 is absorbed from the gastrointestinal tract, as evidenced by marked growth-promoting effects even in short-term tests in mature rats, and absorption is likely to be still higher in infants. Converging lines of evidence incriminate IGF-1 in rBGH milk as a potential risk factor for both breast and gastrointestinal cancers.

Biotechnology domain

Biotechnology and the use of biologically based agents for the betterment of mankind is an active field which is founded on the interaction between many basic sciences. This is achieved in coordination with engineering and technology for scaling up purposes. The application of modern recombinant DNA technology gave momentum and new horizons to the field of biotechnology both in the academic setting and in industry. The applications of biotechnology are being used in many fields including agriculture, medicine, industry, marine science and the environment. The final products of biotechnological applications are diverse. In the medical applications of biotechnology, for example, the field has been evolving in such a way that the final product could be a small molecule (e.g. drug/antibiotic) that can be developed based on genetic information by drug design or drug screening using a cloned and expressed target protein.

Somatotropin and insulin-like growth factor-I concentrations in plasma and milk after daily or sustained-release exogenous somatotropin administrations

Effects of daily injectable or sustained-release bovine somatotropin (bST) administrations on plasma and milk bST and insulin-like growth factor-I (IGF-I) concentrations were monitored in 74 lactating cows through early, mid- and late lactation. Treatments beginning at wk 4 of lactation were excipient (CO, 24 cows) at 2 wk intervals, daily injections of 10.3 mg bST (DI, 25 cows) and 350 mg sustained-release bST at 2 wk intervals (SR, 25 cows). The duration of treatments was 40 wk. Data were first analyzed for the overall mean concentrations covering the 40 wk treatment period. Overall mean plasma bST, milk bST and plasma IGF-I concentrations were significantly increased by both bST treatments (p < 0.05). On the other hand, milk IGF-I concentrations were significantly increased (p < 0.05) only in the DI group. Next, data were analyzed according to stage of lactation. The bST treatments resulted in significant increases (p < 0.05) in plasma and milk bST concentrations for all early, mid- and late lactation periods. Even though plasma IGF-I concentrations were higher (p < 0.05) in all lactation periods for bST treatment groups, higher milk IGF-I concentrations (p < 0.05) occurred only in mid- and late lactation periods for the DI group. The patterns of bST and IGF-I concentrations in milk follows those of the plasma after bST treatments.

Mechanisms of non-genotoxic carcinogenesis

Until recently, the mechanism of carcinogenesis has been regarded as a two-stage phenomenon involving damage to the genetic material, which initiates the process, followed by a cell-division stimulus, which promotes the development of the tumour. However, exposure to some chemicals has been shown to result in carcinogenesis without involvement of the initiation step. The mechanism of non-genotoxic carcinogenesis is not fully understood, but is believed to involve stimulation of cell division with a consequent increased probability of a mutation occurring spontaneously. In this article, Ian Shaw and Huw Jones review the theories of non-genotoxic carcinogenesis with reference to specific examples of known non-genotoxic carcinogens.

The regulatory environment past and future--incentive or impediment to developments in food science and technology: a perspective from FDA

The best system for protecting public health is one that involves two layers of control before food reaches the consumer. The first layer of control is the industry's clear responsibility to prepare food that is safe. The second layer of control is the monitoring that is provided by government to ensure that the industry is doing its job and is in fact producing safe food. While some may view this "second layer" as an impediment in the development and marketing of new technologies, there is another way to look at the "regulatory environment". The regulatory environment itself, is not an impediment to the development of food science and technology. The regulatory environment, with all its components--scientists, consumers, industry, and Congress--defines "safety" within the context of today's technology, scientific capability, and tolerance level of the lay public. The entire regulatory environment serves to guide the development of food science and technology by providing signposts, in the form of scientifically sound regulatory decisions. The scientific basis of these decisions becomes building blocks on which to rest further refinement of the technology, product, ingredient, or packaging material or on which research in related technologies or research in innovative directions can build. This scientific groundwork becomes very important as more and more companies move away from having self-contained research laboratories toward using commercial laboratories and academic institutions, as well as participating in cooperative research endeavors to meet food safety and product development research needs.(ABSTRACT TRUNCATED AT 250 WORDS)

Production and characterization of recombinant turkey prolactin

1. Recombinant turkey prolactin (rctPRL) was produced as a fusion protein in E. coli, purified by affinity chromatography followed by cleavage with thrombin. The final yield of the released rctPRL (> 90% purity) was 1-2 mg/l of bacterial culture. 2. Recombinant tPRL co-migrated with the main immunoreactive band (25 kDa) in turkey pituitary extracts and was identical to natural tPRL except for the addition of three amino acids (Gly-Ser-Ser) resulting from the cloning strategy at the amino terminal end. 3. The bioactivity of the rctPRL was equipotent to ovine PRL in a rabbit mammary explant system and in the Nb2 lymphoma mitogenic assay.

Selective changes in oxidative xenobiotic metabolism in vivo and in vitro after parenteral administration of recombinant bovine somatotrophin to rats

Effects of recombinant bovine somatotrophin (rBST) on in vivo and in vitro oxidative drug metabolism were studied in male rats. rBST was given subcutaneously at a dose of 250 or 500 micrograms 100 g-1 bodyweight 24 h-1 in different dosage patterns. Sulphadimidine (SDD) plasma clearance, urinary excretion of 6-hydroxy-SDD and the in vitro microsomal SDD-hydroxylations were only inhibited when rBST was given in three injections per 24 hours. The hepatic microsomal ethylmorphine N-demethylation rate and the testosterone hydroxylation rate at the 6 beta position were significantly reduced after one rBST injection per 24 hours. Microsomal testosterone hydroxylation rates at the 16 alpha and 2 alpha-positions were reduced depending on the frequency of rBST administration. It is concluded that the inhibition of in vivo and in vitro drug oxidation in rats by rBST is associated with selective changes in activity of cytochrome P450 enzymes in the liver.

Recombinant bovine and porcine somatotropin: safety and benefits of these biotechnologies

This article reviews the literature about the safety and benefits of two recombinantly derived proteins, bovine somatotropin (bST) and porcine somatotropin (pST), that likely will be used in animal agriculture in the future. When administered to dairy cows, bST increases milk production per cow approximately 15% to 20% and improves productive efficiency approximately 10%. Administration of pST to growing pigs reduces carcass fat content by as much as 70% to 80% and improves productive efficiency 15% to 35%. Because meat is a major source of total fat and saturated fatty acids in the diets of human beings, pST will allow consumers to include leaner, more nutrient-dense pork in their diets and still meet current dietary guidelines. Although these biotechnologies have not yet received regulatory approval from the Food and Drug Administration (FDA) for commercial use, information published by the FDA, the National Institutes of Health, the US Congress Office of Technology Assessment, and the American Academy of Pediatrics, as well as an extensive body of scientific evidence, indicate that these products are safe for the consumer. Nonetheless, it is important that consumers understand the benefits and safety of these biotechnologies. Dietitians can play an important role in providing information to consumers about the safety and benefits of bST and pST.

Conventional and nonconventional uses of growth hormone

Although GH has been available as a therapeutic agent for the GH-deficient child for more than 30 years, the conditions of its use have yet to be optimized. The availability of biosynthetic material has provided researchers with the opportunity to develop the protocols necessary to begin to finally answer the most fundamental questions pertaining to dose, frequency, and duration of treatment. It has also permitted the initiation of prospective trials in a large number of conditions that result in childhood short stature, with the expectation that some or many of them will be treated effectively and safely. Finally, it has opened the door to an entire spectrum of potentially new uses of GH and other growth factors for so-called nonconventional indications. That these have implications that range from the short-term rapid healing of a burn graft site, to the more efficient induction of ovulation, to the long-term preservation of lean body mass has excited the interest of investigators in many fields of medicine and physiology. Thus, the recent progress reported in this paper is really the beginning of the new research that will take place with GH and growth factors.

Bovine somatotropin: review of an emerging animal technology

One of the first potential biotechnology products for animal production is bST. Research in the technology of bST has involved scientists and support from federal agencies, universities, and private industry. As a consequence of this extensive cooperation, more than 1000 bST studies have been conducted, which involved over 20,000 dairy cows, and results have been confirmed by scientists throughout the world. This quantity of published research is unprecedented for a new technology and greater than most dairy technologies in use. In contrast to steroids, bST is a protein hormone. Milk yield and persistency responses to bST have been observed for all dairy breeds examined. Quality of management is the major factor affecting magnitude of milk response to bST. The mechanism of action of bST involves a series of orchestrated changes in the metabolism of body tissues so that more nutrients can be used for milk synthesis. It is these coordinated changes that allow the animal to achieve an increased milk yield while remaining normal and healthy. Bioenergetic studies demonstrated that bST-supplemented animals are not stressed. Similarly, there are no adverse health effects from bST even under poor management conditions. Composition of milk (fat, protein, lactose, cholesterol, minerals, and vitamins) is not substantially altered when bST is used and does not differ in manufacturing characteristics. Public perception is of paramount importance if bST or any new technology is to be effectively implemented. New technology must be understood and perceived as safe and beneficial both by farmers, who would utilize it, and consumers, who would purchase the dairy products. With bST use, a unit of milk is produced with less feed and protein supplement and with a reduction in animal excreta (manure, urine, and methane). Nationally, the use of bST simply reinforces, but does not fundamentally change, dairy industry trends of increased milk yield per cow, reduced number of cows, and declining dairy farm numbers. For individual farms, bST technology is size-neutral. However, poorly managed farms where animals are stressed, underfed, or sick are at an economic disadvantage because they will achieve negligible milk response to bST.

Effect of high doses of a sustained-release bovine somatotropin on antibody formation in dairy cows

Eighty-two lactating Holstein cows received either one, three, or five concurrent, intramuscular injections of a unit dose (.6 g) of zinc methionyl bST (some-tribove) or five doses of the vehicle. Injections were administered at 14-d intervals from 60 d postpartum until the end of lactation or necropsy. Thirty-eight cows continued on the same treatment for a 2nd yr. Blood bST antibodies developed within the first 7 wk of treatment, and the number of cows with anti-bST binding generally declined with time. Thirteen out of 59 cows receiving bST developed binding activity > 25% (positives) during the 1st yr. At the .6-g dose level, no binding was detected after wk 15. Seven of the 13 positive cows were among the group randomly selected to continue on study during yr 2. In the 2nd yr, only 2 out of 24 bST-treated cows were positive. Binding activity was associated with the IgG fraction in serum. Binding capacities of antibodies ranged from .625 to 3.04 mg of bST/L, and affinities ranged from 1.14 x 10(8) to 3.14 x 10(8) L/mol. Cows considered to be clinically positive had performance similar to those of their herdmates having binding < 25%. No evidence of a pathologic effect of antibodies existed in treated cows, their calves, or fetuses. The presence of anti-bST antibodies did not affect milk production of the cow or growth of the calves conceived during bST treatment.

Epidermal growth factor in human and bovine milk

The concentration of epidermal growth factor in human and bovine milk was measured by radioreceptor assay. Both human placental plasma membranes and a human epidermoid carcinoma cell were used as the epidermal growth factor receptor source in the assay. The use of placental plasma membrane in the radioreceptor assay gave erroneous results for bovine milk and overestimated the concentration of epidermal growth factor in human milk. Intact cells appear to provide a more accurate measure of the concentration of epidermal growth factor in milk samples. Using A431 cells, we found very low concentrations of epidermal growth factor in bovine milk (less than 2 ng/ml) compared to human milk (30-40 ng/ml). No epidermal growth factor activity was found in several cows' milk-based infant formulas. These results highlight the caution which must be taken when measuring trace substances such as polypeptide growth factors in complex samples such as milk.

Bovine somatotropin

Bovine somatotropin has the potential to alter profoundly the way that dairy herds are managed and to change the ways in which veterinarians provide services to those herds. This article describes the structure, function, and action of somatotropin. The metabolic effects of somatotropin on dairy cattle are discussed.

Management of the dairy herd treated with bovine somatotropin

Cows that produce large quantities of milk require more management and higher quality of management than cows producing smaller quantities of milk. This is true whether improvements in milk production occur through genetic selection, increased milking frequency, or use of bovine somatotropin (bST). The milk response to use of bST is similar (10 to 15%) to that of three times a day (3x) milking and we expect that the management required to maintain the increased production through successive lactations with bST will be similar to that required for the 3x herd. Maximum economic benefit from use of bST will be achieved by dairy managers who (1) feed cows to maximize intake of diets with appropriate nutrient content and balance, (2) maintain proper body condition of their cows, and (3) have health and reproduction management programs that prevent rather than cure problems. Efficient use of record-keeping systems that enable the manager to monitor individual cow status will be advantageous. Economic forces will continue to bring change to the dairy industry. The manager that plans for change and ensures that the dairy's management programs allow for the most economically efficient production will be in position to adapt to these changes. The well-managed dairy will be able to adopt new, efficiency-enhancing technologies, such as bST, to ensure the continued opportunity to compete in the dairy industry.

The pituitary gland is required for protection against lethal effects of Salmonella typhimurium

One-half of pituitary-intact or sham-operated rats survive infection with 10(9) colony-forming units of Salmonella typhimurium, whereas rats without a pituitary gland all die within a few days. When the dose of S. typhimurium is reduced 600-fold, 15-25% of the hypophysectomized rats survive, and the survival rate is significantly enhanced by administration of tetracycline, recombinant interferon gamma (IFN-gamma), or recombinant growth hormone (GH). The protective effect of GH is abolished by heat inactivation or with an antibody to GH. Spleens from normal and hypophysectomized rats treated with tetracycline, IFN-gamma, or GH have 59-99% fewer bacteria 5 days after infection as compared to control rats. Peritoneal macrophages from hypophysectomized rats that are infected in vitro with S. typhimurium kill half as many extracellular bacteria as compared to pituitary-intact rats, and this bactericidal capacity is significantly augmented 75-95% by either GH or IFN-gamma. These data establish that the pituitary gland is essential for homeostasis during an infectious episode and that GH plays an important role in host resistance by augmenting the ability of macrophages to kill S. typhimurium.